Two weeks after the European Medicines Agency (EMEA) decided the risks of Sanofi-Aventis’ weight-loss drug Acomplia are greater than the benefits and recommended suspending its marketing authorization, the company decided to discontinue its development.Read More

Pfizer is terminating its Phase III development program for its investigational compound CP-945,598 for weight management.Read More

SciClone Pharmaceuticals’ Phase III study evaluating thymalfasin did not meet its main objective in treating patients with hepatitis C (HCV).Read More

Tarceva significantly extended the time patients with advanced nonsmall cell lung cancer (NSCLC) lived without their cancer getting worse, according to a joint statement by Genentech and OSI Pharmaceuticals.Read More

Sciele Pharma received positive findings from its Phase III trial of PSD502 as a treatment for premature ejaculation.Read More

Johnson & Johnson’s (J&J) Phase II clinical trial of the experimental anticoagulant rivaroxaban yielded encouraging response rates as a treatment for acute coronary syndrome, the company said.Read More

VIA Pharmaceuticals saw positive results from two Phase II trials using VIA-2291 to treat cardiovascular disease.Read More

Cytokinetics received favorable outcomes from its Phase IIa trial of CK-1827452 in stable heart failure patients. Read More

EyeGate Pharma has enrolled its first patient in a Phase II clinical trial of EGP-437 for treating mild-to-moderate dry eye.Read More

Molecular Insight Pharmaceuticals received data from its Phase IIb trial that suggests adding Zemiva with quantitative single photon emission computed tomography imaging may help identify chest pain in patients at high risk for acute coronary syndrome (ACS).Read More